Neutralizing antibodies (NABS) and interferon beta-1b therapy of multiple sclerosis.
Horowski
R
R
SBU Therapeutics, Schering AG Berlin, Germany. Reinhard.Horowski@Schering.de
Stürzebecher
C S
CS
Kapp
J F
JF
D000276:Adjuvants, Immunologic / Q000627:therapeutic use*; D000906:Antibodies / Q000032:analysis / Q000276:immunology*; D000917:Antibody Formation; D003430:Cross-Sectional Studies; D004305:Dose-Response Relationship, Drug; D006801:Humans; D000068556:Interferon beta-1a; D000068576:Interferon beta-1b; D016899:Interferon-beta / Q000276:immunology / Q000627:therapeutic use*; D009103:Multiple Sclerosis / Q000188:drug therapy* / Q000276:immunology*; D009500:Neutralization Tests; D012189:Retrospective Studies; D016896:Treatment Outcome
D000276:Adjuvants, Immunologic; D000906:Antibodies; D000068576:Interferon beta-1b; D016899:Interferon-beta; D000068556:Interferon beta-1a